Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology

Seminars in Immunopathology

Volumn 39, Issue 5, 2017, Pages 529-539

  Channappanavar, Rudragouda ^a   Perlman, Stanley ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Cytokine storm; Immunopathology; Interferon; MERS CoV; Monocyte macrophage; SARS CoV

Indexed keywords

ALPHA BETA INTERFERON RECEPTOR; ANTIVIRUS AGENT; CHEMOKINE; CORTICOSTEROID; CYTOKINE; IMIQUIMOD; IMMUNOMODULATING AGENT; INTERFERON; PEGINTERFERON LAMBDA; PHOSPHOLIPID; SPHINGOSINE 1 PHOSPHATE RECEPTOR 1 AGONIST; UNCLASSIFIED DRUG;

ADULT RESPIRATORY DISTRESS SYNDROME; ANTIVIRAL ACTIVITY; APOPTOSIS; CELL FUNCTION; CIRCOVIRIDAE INFECTION; CLINICAL FEATURE; CORONAVIRUS INFECTION; CORTICOSTEROID THERAPY; CYTOKINE STORM; DISEASE ASSOCIATION; DISEASE SEVERITY; ENDOTHELIUM CELL; EPITHELIUM CELL; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOPATHOLOGY; INFECTION RESISTANCE; INFLUENZA A; LUNG ALVEOLUS EPITHELIUM CELL; LUNG DISEASE; MACROPHAGE ACTIVATION; MICROSCOPY; MIDDLE EAST RESPIRATORY SYNDROME; MONOCYTE; MONOCYTE FUNCTION; MONOCYTE MACROPHAGE ACCUMULATION; MONOCYTE RECRUITMENT; NEUTROPHIL ACCUMULATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; VIRUS REPLICATION; ANIMAL; CORONAVIRINAE; CYTOLOGY; DISEASE MODEL; DISEASE PREDISPOSITION; DRUG EFFECTS; IMMUNOLOGY; INNATE IMMUNITY; LUNG; MACROPHAGE; METABOLISM; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHENOTYPE; PHYSIOLOGY; SEVERITY OF ILLNESS INDEX; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; CHEMOKINES; COMBINED MODALITY THERAPY; CORONAVIRUS; CORONAVIRUS INFECTIONS; CYTOKINES; DISEASE MODELS, ANIMAL; DISEASE SUSCEPTIBILITY; HUMANS; IMMUNE SYSTEM; IMMUNITY, INNATE; INTERFERONS; LUNG; MACROPHAGES; MONOCYTES; PHENOTYPE; SEVERITY OF ILLNESS INDEX; VIRUS REPLICATION;

EID: 85018428316     PISSN: 18632297     EISSN: 18632300     Source Type: Journal    
DOI: 10.1007/s00281-017-0629-x     Document Type: Review

References (132)

1. Masters PS, Perlman, S (2013) Coronaviridae. In: Knipe DM, Howley P (eds) Fields Virology. Lippincott Williams and Wilkins, Philadelphia, PA, pp 825–858
2. Siddell SZJ, Snijder EJ (2005) Coronaviruses, toroviruses, and arteriviruses, vol. 1. Hodder Arnold, London
3. Peck KM et al (2015) Coronavirus host range expansion and Middle East respiratory syndrome coronavirus emergence: biochemical mechanisms and evolutionary perspectives. Annu Rev Virol 2(1):95–117
4. Su S et al (2016) Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol 24(6):490–502
5. Weiss SR, Navas-Martin S (2005) Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol Mol Biol Rev 69(4):635–664
6. Heugel J et al (2007) Coronavirus-associated pneumonia in previously healthy children. Pediatr Infect Dis J 26(8):753–755
7. Kuypers J et al (2007) Clinical disease in children associated with newly described coronavirus subtypes. Pediatrics 119(1):e70–e76
8. Drosten C et al (2003) Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 348(20):1967–1976
9. Kuiken T et al (2003) Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet 362(9380):263–270
10. Peiris JS et al (2003) Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361(9366):1319–1325
11. van Boheemen S et al (2012) Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. MBio 3(6)
12. Zaki AM et al (2012) Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 367(19):1814–1820
13. Perlman S, Netland J (2009) Coronaviruses post-SARS: update on replication and pathogenesis. Nat Rev Microbiol 7(6):439–450
14. WHO Cumulative number of reported probable cases of SARS. In: 2003
15. http://www.who.int/csr/disease/coronavirus_infections/MERS_CoV_RA_20140613.pdf WUoM-CTfAtHaIRfA-RGLaoMAf
16. WHO: Middle East respiratory syndrome coronavirus (MERS-CoV). http://www.who.int/emergencies/mers-cov/en/
17. Adney DR et al (2014) Replication and shedding of MERS-CoV in upper respiratory tract of inoculated dromedary camels. Emerg Infect Dis 20(12):1999–2005
18. Alagaili AN et al (2014) Middle East respiratory syndrome coronavirus infection in dromedary camels in Saudi Arabia. MBio 5(2):e00884–e00814
19. Ge XY et al (2013) Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature 503(7477):535–538
20. Menachery VD et al (2015) A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. Nat Med 21(12):1508–1513
21. Arabi YM et al (2014) Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection. Ann Intern Med 160(6):389–397
22. Assiri A et al (2013) Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis 13(9):752–761
23. Leong HN et al (2006) Clinical and laboratory findings of SARS in Singapore. Ann Acad Med Singap 35(5):332–339
24. Saad M et al (2014) Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia. Int J Infect Dis 29:301–306
25. Al-Tawfiq JA et al (2014) Middle East respiratory syndrome coronavirus: a case-control study of hospitalized patients. Clin Infect Dis 59(2):160–165
26. Zumla A et al (2015) Middle East respiratory syndrome. Lancet 386(9997):995–1007
27. Peiris JS et al (2004) Severe acute respiratory syndrome. Nat Med 10(12 Suppl):S88–S97
28. Peiris JS et al (2003) Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 361(9371):1767–1772
29. Nicholls J et al (2003) SARS: clinical virology and pathogenesis. Respirology 8(Suppl):S6–S8
30. van den Brand JM et al (2014) The pathology and pathogenesis of experimental severe acute respiratory syndrome and influenza in animal models. J Comp Pathol 151(1):83–112
31. Gu J et al (2005) Multiple organ infection and the pathogenesis of SARS. J Exp Med 202(3):415–424
32. Nicholls JM et al (2003) Lung pathology of fatal severe acute respiratory syndrome. Lancet 361(9371):1773–1778
33. van den Brand JM et al (2014) The pathology and pathogenesis of experimental severe acute respiratory syndrome and influenza in animal models. J Comp Pathol 151(1):83–112
34. Cui W et al (2003) Expression of lymphocytes and lymphocyte subsets in patients with severe acute respiratory syndrome. Clin Infect Dis 37(6):857–859
35. Li T et al (2004) Significant changes of peripheral T lymphocyte subsets in patients with severe acute respiratory syndrome. J Infect Dis 189(4):648–651
36. Wang YH et al (2004) A cluster of patients with severe acute respiratory syndrome in a chest ward in southern Taiwan. Intensive Care Med 30(6):1228–1231
37. Ng DL et al (2016) Clinicopathologic, immunohistochemical, and ultrastructural findings of a fatal case of Middle East respiratory syndrome coronavirus infection in the United Arab Emirates, April 2014. Am J Pathol 186(3):652–658
38. Channappanavar R et al (2016) Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice. Cell Host Microbe 19(2):181–193
39. Davidson S et al (2015) Disease-promoting effects of type I interferons in viral, bacterial, and coinfections. J Interf Cytokine Res 35(4):252–264
40. Shaw AC et al (2013) Age-dependent dysregulation of innate immunity. Nat Rev Immunol 13(12):875–887
41. Cheung CY et al (2005) Cytokine responses in severe acute respiratory syndrome coronavirus-infected macrophages in vitro: possible relevance to pathogenesis. J Virol 79(12):7819–7826
42. Law HK et al (2005) Chemokine up-regulation in SARS-coronavirus-infected, monocyte-derived human dendritic cells. Blood 106(7):2366–2374
43. Yen YT et al (2006) Modeling the early events of severe acute respiratory syndrome coronavirus infection in vitro. J Virol 80(6):2684–2693
44. Chien JY et al (2006) Temporal changes in cytokine/chemokine profiles and pulmonary involvement in severe acute respiratory syndrome. Respirology 11(6):715–722
45. Wang CH et al (2005) Persistence of lung inflammation and lung cytokines with high-resolution CT abnormalities during recovery from SARS. Respir Res 6:42
46. Wong CK et al (2004) Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol 136(1):95–103
47. Zhang Y et al (2004) Analysis of serum cytokines in patients with severe acute respiratory syndrome. Infect Immun 72(8):4410–4415
48. Cameron MJ et al (2008) Human immunopathogenesis of severe acute respiratory syndrome (SARS). Virus Res 133(1):13–19
49. Cameron MJRL, Xu L, Danesh A, Bermejo-Martin JF, Cameron CM, Muller MP, Gold WL, Richardson SE, Poutanen SM, Willey BM, DeVries ME, Fang Y, Seneviratne C, Bosinger SE, Persad D, Keshavjee S, Louie M, Loeb MB, Brunton J, McGeer AJ, Kelvin DJ (2007) Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome. J Virol 81(16):8692–8706
50. Huang KJ et al (2005) An interferon-gamma-related cytokine storm in SARS patients. J Med Virol 75(2):185–194
51. Theron M et al (2005) A probable role for IFN-gamma in the development of a lung immunopathology in SARS. Cytokine 32(1):30–38
52. Lau SK et al (2013) Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment. J Gen Virol 94(Pt 12):2679–2690
53. Chu H et al (2015) Middle East respiratory syndrome coronavirus efficiently infects human primary T lymphocytes and activates the extrinsic and intrinsic apoptosis pathways. J Infect Dis 213(6):904–14
54. Tynell J et al (2016) Middle East respiratory syndrome coronavirus shows poor replication but significant induction of antiviral responses in human monocyte-derived macrophages and dendritic cells. J Gen Virol 97(2):344–355
55. Zhou J et al (2014) Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: implications for pathogenesis. J Infect Dis 209(9):1331–1342
56. Scheuplein VA et al (2015) High secretion of interferons by human plasmacytoid dendritic cells upon recognition of Middle East respiratory syndrome coronavirus. J Virol 89(7):3859–3869
57. Kim ES et al (2016) Clinical progression and cytokine profiles of Middle East respiratory syndrome coronavirus infection. J Korean Med Sci 31(11):1717–1725
58. Min CK et al (2016) Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity. Sci Rep 6:25359
59. Roberts A et al (2005) Aged BALB/c mice as a model for increased severity of severe acute respiratory syndrome in elderly humans. J Virol 79(9):5833–5838
60. Day CW et al (2009) A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo. Virology 395(2):210–222
61. Nagata N et al (2008) Mouse-passaged severe acute respiratory syndrome-associated coronavirus leads to lethal pulmonary edema and diffuse alveolar damage in adult but not young mice. Am J Pathol 172(6):1625–1637
62. Roberts A et al (2007) A mouse-adapted SARS-coronavirus causes disease and mortality in BALB/c mice. PLoS Pathog 3(1):e5
63. Frieman MB et al (2010) SARS-CoV pathogenesis is regulated by a STAT1 dependent but a type I, II and III interferon receptor independent mechanism. PLoS Pathog 6(4):e1000849
64. Zhao J et al (2011) Age-related increases in PGD(2) expression impair respiratory DC migration, resulting in diminished T cell responses upon respiratory virus infection in mice. J Clin Invest 121(12):4921–4930
65. Graham RL et al (2012) A live, impaired-fidelity coronavirus vaccine protects in an aged, immunocompromised mouse model of lethal disease. Nat Med 18(12):1820–1826
66. Rockx B et al (2009) Early upregulation of acute respiratory distress syndrome-associated cytokines promotes lethal disease in an aged-mouse model of severe acute respiratory syndrome coronavirus infection. J Virol 83(14):7062–7074
67. Smits SL et al (2010) Exacerbated innate host response to SARS-CoV in aged non-human primates. PLoS Pathog 6(2):e1000756
68. Totura AL et al (2015) Toll-like receptor 3 signaling via TRIF contributes to a protective innate immune response to severe acute respiratory syndrome coronavirus infection. MBio 6(3):e00638–e00615
69. Jimenez-Guardeno JM et al (2014) The PDZ-binding motif of severe acute respiratory syndrome coronavirus envelope protein is a determinant of viral pathogenesis. PLoS Pathog 10(8):e1004320
70. Nieto-Torres JL et al (2014) Severe acute respiratory syndrome coronavirus envelope protein ion channel activity promotes virus fitness and pathogenesis. PLoS Pathog 10(5):e1004077
71. Nieto-Torres JL et al (2015) Severe acute respiratory syndrome coronavirus E protein transports calcium ions and activates the NLRP3 inflammasome. Virology 485:330–339
72. de Wit E et al (2013) Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques. Proc Natl Acad Sci U S A 110(41):16598–16603
73. Haagmans BL et al (2015) Asymptomatic Middle East respiratory syndrome coronavirus infection in rabbits. J Virol 89(11):6131–6135
74. Houser KV et al (2016) Prophylaxis with a Middle East respiratory syndrome coronavirus (MERS-CoV)-specific human monoclonal antibody protects rabbits from MERS-CoV infection. J Infect Dis 213(10):1557–1561
75. Falzarano D et al (2014) Infection with MERS-CoV causes lethal pneumonia in the common marmoset. PLoS Pathog 10(8):e1004250
76. Johnson RF et al (2015) Intratracheal exposure of common marmosets to MERS-CoV Jordan-n3/2012 or MERS-CoV EMC/2012 isolates does not result in lethal disease. Virology 485:422–430
77. Barlan A et al (2014) Receptor variation and susceptibility to Middle East respiratory syndrome coronavirus infection. J Virol 88(9):4953–4961
78. Zhao J et al (2014) Rapid generation of a mouse model for Middle East respiratory syndrome. Proc Natl Acad Sci U S A 111(13):4970–4975
79. Gretebeck LM, Subbarao K (2015) Animal models for SARS and MERS coronaviruses. Curr Opin Virol 13:123–129
80. van Doremalen N, Munster VJ (2015) Animal models of Middle East respiratory syndrome coronavirus infection. Antivir Res 122:28–38
81. Pascal KE et al (2015) Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection. Proc Natl Acad Sci U S A 112(28):8738–8743
82. Cockrell A et al (2016) A mouse model for MERS coronavirus-induced acute respiratory distress syndrome. Nature Microbiology 2:16226
83. Li K et al (2017) Mouse-adapted MERS coronavirus causes lethal lung disease in human DPP4 knockin mice. Proceedings of the National Academy of Sciences 114(15):E3119–E3128
84. Frieman M et al (2007) Severe acute respiratory syndrome coronavirus ORF6 antagonizes STAT1 function by sequestering nuclear import factors on the rough endoplasmic reticulum/Golgi membrane. J Virol 81(18):9812–9824
85. Kindler E et al (2016) Interaction of SARS and MERS coronaviruses with the antiviral interferon response. Adv Virus Res 96:219–243
86. Narayanan K et al (2008) Severe acute respiratory syndrome coronavirus nsp1 suppresses host gene expression, including that of type I interferon, in infected cells. J Virol 82(9):4471–4479
87. Sun L et al (2012) Coronavirus papain-like proteases negatively regulate antiviral innate immune response through disruption of STING-mediated signaling. PLoS One 7(2):e30802
88. Thiel V, Weber F (2008) Interferon and cytokine responses to SARS-coronavirus infection. Cytokine Growth Factor Rev 19(2):121–132
89. Totura AL, Baric RS (2012) SARS coronavirus pathogenesis: host innate immune responses and viral antagonism of interferon. Current Opinion in Virology 2(3):264–275
90. Wathelet MG et al (2007) Severe acute respiratory syndrome coronavirus evades antiviral signaling: role of nsp1 and rational design of an attenuated strain. J Virol 81(21):11620–11633
91. Fehr AR et al (2016) The Conserved Coronavirus Macrodomain Promotes Virulence and Suppresses the Innate Immune Response during Severe Acute Respiratory Syndrome Coronavirus Infection. mBio 7(6):e01721–16
92. Frieman M et al (2009) Severe acute respiratory syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and NF-kappaB signaling. J Virol 83(13):6689–6705
93. Kopecky-Bromberg SA et al (2007) Severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and nucleocapsid proteins function as interferon antagonists. J Virol 81(2):548–557
94. Lu XL et al (2011) SARS-CoV nucleocapsid protein antagonizes IFN-beta response by targeting initial step of IFN-beta induction pathway, and its C-terminal region is critical for the antagonism. Virus Genes 42(1):37–45
95. Siu KL et al (2014) Suppression of innate antiviral response by severe acute respiratory syndrome coronavirus M protein is mediated through the first transmembrane domain. Cell Mol Immunol 11(2):141–149
96. Lui PY et al (2016) Middle East respiratory syndrome coronavirus M protein suppresses type I interferon expression through the inhibition of TBK1-dependent phosphorylation of IRF3. Emerg Microbes Infect 5:e39
97. Yang Y et al (2013) The structural and accessory proteins M, ORF 4a, ORF 4b, and ORF 5 of Middle East respiratory syndrome coronavirus (MERS-CoV) are potent interferon antagonists. Protein Cell 4(12):951–961
98. Chu CM et al (2004) Initial viral load and the outcomes of SARS. CMAJ 171(11):1349–1352
99. Ng ML et al (2003) Proliferative growth of SARS coronavirus in Vero E6 cells. J Gen Virol 84(Pt 12):3291–3303
100. Oh MD et al (2016) Viral load kinetics of MERS coronavirus infection. N Engl J Med 375(13):1303–1305
101. Herold S et al (2008) Lung epithelial apoptosis in influenza virus pneumonia: the role of macrophage-expressed TNF-related apoptosis-inducing ligand. J Exp Med 205(13):3065–3077
102. Hogner K et al (2013) Macrophage-expressed IFN-beta contributes to apoptotic alveolar epithelial cell injury in severe influenza virus pneumonia. PLoS Pathog 9(2):e1003188
103. Rodrigue-Gervais IG et al (2014) Cellular inhibitor of apoptosis protein cIAP2 protects against pulmonary tissue necrosis during influenza virus infection to promote host survival. Cell Host Microbe 15(1):23–35
104. Zhao J et al (2010) T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice. J Virol 84(18):9318–9325
105. Kim KD et al (2007) Adaptive immune cells temper initial innate responses. Nat Med 13(10):1248–1252
106. Palm NW, Medzhitov R (2007) Not so fast: adaptive suppression of innate immunity. Nat Med 13(10):1142–1144
107. Zornetzer GA et al (2010) Transcriptomic analysis reveals a mechanism for a prefibrotic phenotype in STAT1 knockout mice during severe acute respiratory syndrome coronavirus infection. J Virol 84(21):11297–11309
108. Page C et al (2012) Induction of alternatively activated macrophages enhances pathogenesis during severe acute respiratory syndrome coronavirus infection. J Virol 86(24):13334–13349
109. Gralinski LE et al (2015) Genome wide identification of SARS-CoV susceptibility loci using the collaborative cross. PLoS Genet 11(10):e1005504
110. Drosten C et al (2013) Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection. Lancet Infect Dis 13(9):745–751
111. Lew TW et al (2003) Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome. JAMA 290(3):374–380
112. Jiang Y et al (2005) Characterization of cytokine/chemokine profiles of severe acute respiratory syndrome. Am J Respir Crit Care Med 171(8):850–857
113. Reghunathan R et al (2005) Expression profile of immune response genes in patients with Severe Acute Respiratory Syndrome. BMC Immunology 6:2
114. Stockman LJ et al (2006) SARS: systematic review of treatment effects. PLoS Med 3(9):e343
115. Al-Tawfiq JA et al (2014) Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study. Int J Infect Dis 20:42–46
116. Falzarano D et al (2013) Treatment with interferon-alpha2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med 19(10):1313–1317
117. Omrani AS et al (2014) Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infect Dis 14(11):1090–1095
118. Auyeung TW et al (2005) The use of corticosteroid as treatment in SARS was associated with adverse outcomes: a retrospective cohort study. J Infect 51(2):98–102
119. Ho JC et al (2003) High-dose pulse versus nonpulse corticosteroid regimens in severe acute respiratory syndrome. Am J Respir Crit Care Med 168(12):1449–1456
120. Yam LY et al (2007) Corticosteroid treatment of severe acute respiratory syndrome in Hong Kong. J Infect 54(1):28–39
121. Haagmans BL et al (2004) Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques. Nat Med 10(3):290–293
122. Zumla A et al (2016) Coronaviruses—drug discovery and therapeutic options. Nat Rev Drug Discov 15(5):327–47
123. Davidson S et al (2016) IFNlambda is a potent anti-influenza therapeutic without the inflammatory side effects of IFNalpha treatment. EMBO Mol Med 8(9):1099–1112
124. Blazek K et al (2015) IFN-lambda resolves inflammation via suppression of neutrophil infiltration and IL-1beta production. J Exp Med 212(6):845–853
125. Imai Y et al (2008) Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell 133(2):235–249
126. Shirey KA et al (2013) The TLR4 antagonist Eritoran protects mice from lethal influenza infection. Nature 497(7450):498–502
127. Teijaro JR et al (2011) Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection. Cell 146(6):980–991
128. Walsh KB et al (2011) Suppression of cytokine storm with a sphingosine analog provides protection against pathogenic influenza virus. Proc Natl Acad Sci U S A 108(29):12018–12023
129. Leuschner F et al (2015) Silencing of CCR2 in myocarditis. Eur Heart J 36(23):1478–1488
130. Leuschner F et al (2011) Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat Biotechnol 29(11):1005–1010
131. Darwish I et al (2011) Immunomodulatory therapy for severe influenza. Expert Rev Anti-Infect Ther 9(7):807–822
132. McDermott JE et al (2016) The effect of inhibition of PP1 and TNFalpha signaling on pathogenesis of SARS coronavirus. BMC Syst Biol 10(1):93